Recently added articles from Biotech Business:
ENDOCYTE PATENT ON VITAMIN RECEPTOR BINDING ANTI-CANCER AGENTS.
Dec 01, 2009 ... Endocyte awarded patent for vitamin receptor binding=20 drug delivery conjugates Endocyte, Inc., West Lafayette. Ind., a cancer drug discovery and development company, has been awarded a patent from the United States Patent and Trademark Office covering vitamin receptor binding anti-cancer ...
ENDOCYTE PRESENTS DATA ON EC145 FOR OVAVIAN CANCER.
Dec 01, 2009 ... Endocyte, Inc., a cancer drug discovery and development company, presented data from a Phase 2a clinical trial for EC145, currently in development as a potential treatment for advanced ovarian cancer. Results were presented at the European Society of Gynaecologic Oncology (ESGO) meeting in ...
ROCKWELL MEDICAL COMPLETES SFP PHASE 11B CLINICAL STUDY.
Dec 01, 2009 ... Rockwell Medical (Nasdaq:RMTI), Wixom, Mich., a fully- integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, has announced that the last patient has completed the ...
IRIS INTERNATIONAL INITIATES PROSVUE STUDY FOR PROSTATE CANCER.(Report)
Dec 01, 2009 ... IRIS International, Inc. (Nasdaq:IRIS), Chatsworth, Calif., has received Institutional Review Board (IRB) approvals from Duke University Medical Center, Memorial Sloan Kettering Cancer Institute, Eastern Virginia Medical School and the University of Washington Medical Center to immediately ...
EXCELIMMUNE AWARDED NIH SBIR GRANT FOR ANTIBODY THERAPY.
Dec 01, 2009 ... Excelimmune, Inc. has announced that the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant to support research aimed at developing new treatments for Clostridium difficile (C. difficile) infection, employing Excelimmune's ...